FIELD: medicine.
SUBSTANCE: enzyme immunoassay is conducted to determine a quantitative level of patient's oral fluid biomarkers prior to or at least 30 minutes after meals. The biomarker is matrix metalloproteinase (MMP 8) or matrix metalloproteinase (MMP 9). For a clinical reference group, MMP 8 is taken at 21.65-41.85 ng/ml; if the level is 171.25-524.7 ng/ml, a low adaptability is diagnosed, whereas the value of 58.7-162.7 ng/ml shows a complete functional adaptation of the patient suffering dentofacial new growths to removable palatal dentures. For a clinical reference group, MMP 9 is taken at 134.9-207.7 ng/ml; if the level is 526.5-919.1 ng/ml, a low adaptability is diagnosed, whereas the value of 236.8-492.3 ng/ml shows a complete functional adaptation of the patient suffering dentofacial new growths to removable palatal dentures.
EFFECT: invention enables providing more accurate instant diagnosis for the adaptability to removable palatal dentures in the patients suffering dentofacial new growth on the day of visiting a doctor.
3 cl, 6 ex
